Fannin Innovation Studio is actively seeking Therapeutics interns and has an Open House coming up on May 26th
Fannin primarily in-licenses promising, early-stage therapeutic and medical device technologies from leading academic investigators in the Texas Medical Center and on a national stage. Fannin develops and de-risks these technologies via preclinical work and engineering up through early clinical trials. Additionally, Fannin builds the business model and use case, resulting in strategic partnerships or acquisitions.
Our internship program provides hands-on operational experience in early-stage life science development. Fannin offers two tracks in our internship program: Therapeutics and Medical Devices. Our interns work closely with established and potential portfolio companies, experientially learning about biomedical commercialization. Interns might be tasked with assisting with due diligence, working on market analysis, assisting with product development, or researching and understanding key regulatory requirements. All interns work closely with the core Fannin team to ensure a beneficial and useful experience.
We have had many interns and Fellows complete our program, and we look forward to receiving interest from more of your members!
Questions? Contact Serena Miggins or Stephanie Vega
https://fannininnovation.com/careers/
- New model predicts mRNA protein production, accelerating drug and vaccine discovery
A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences … - A dual-view deep learning-driven discovery of cinnamoyl anthranilic acid derivatives against …
Three drugs initially authorized for smallpox (Tecovirimat, Cidofovir, and Brincidofovir) are considered potential treatments for mpox; however, … - Making sense of China's R&D ascent – Fierce Pharma
In this week's episode of "The Top Line," we trace China's rapid ascent in R&D and drug discovery and examine how U.S. and European drugmakers are … - Protein Core Stability Rules Open Door for Faster Protein Design
Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development · Moving the Drug Pipeline Forward with Mechanistic Modeling. - Absci Prices $50 Mln Public Offering To Advance AI-Driven Drug Programs – RTTNews
Absci Corporation (ABSI), a clinical-stage biopharma company leveraging generative AI for drug discovery, has priced an underwritten public …